Длительный контроль метастатической уротелиальной карциномы, резистентной к платиносодержащей терапии (клиническое наблюдение)

Abstract

Urothelial carcinoma is the most commonly diagnosed malignant tumor of the bladder and/or upper urinary tract. Besides, bladder cancer is a socially significant disease that occupies the 9th place in the oncopathology structure, in which middle-aged and older men mainly become ill. Anticancer therapy of patients with metastatic urothelial cancer in the first line is currently well studied and has its own standards that are actively used in clinical practice. However, the problem of choosing anticancer therapy for patients with metastatic urothelial cancer in the second line is still relevant. Vinflunine therapy is a possible option for the treatment of such patients. The presented clinical case demonstrated long-term control of metastatic urothelial carcinoma in a 67-year-old male patient resistant to platinum-based therapy. The patient received 24 cycles of vinflunine therapy. Hematological toxicity in the form of anemia and grade 1 neutropenia and non-hematological toxicity — grade 2 asthenia, grade 1 myalgia, grade 2 bone pain, which did not require dose reduction or therapy discontinuation, were noted during treatment with vinflunine. Vinflunine therapy provided stabilization of the oncological process and a decrease in the pain syndrome severity, which allowed to refuse taking analgesics. KEYWORDS: metastatic urothelial carcinoma, bladder cancer, inefficacy of platinum-based chemotherapy, second-line therapy, vinflunine, efficacy, safety, life quality. FOR CITATION: Shatokhina A.S. Long-term control of metastatic urothelial carcinoma resistant to platinum-based therapy: clinical case. Russian Medical Inquiry. 2023;7(6) (in Russ.). DOI: 10.32364/2587-6821-2023-7-6-1.